Proper local therapy for progressive lesions in patients with AR could prolong PFS in NSCLC and thus extend the PD1/PD-L1 inhibitor treatment duration, which is generally related to less toxicity and better quality of life than conventional chemotherapy [1]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.